Last A$0.64 AUD
Change Today 0.00 / 0.00%
Volume 236.5K
UNS On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Stuttgart
As of 2:11 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

unilife corp-cdi (UNS) Snapshot

Open
A$0.65
Previous Close
A$0.64
Day High
A$0.66
Day Low
A$0.64
52 Week High
03/20/14 - A$1.05
52 Week Low
05/2/13 - A$0.30
Market Cap
394.2M
Average Volume 10 Days
684.6K
EPS TTM
--
Shares Outstanding
615.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNILIFE CORP-CDI (UNS)

Related News

No related news articles were found.

unilife corp-cdi (UNS) Related Businessweek News

View More BusinessWeek News

unilife corp-cdi (UNS) Details

Unilife Corporation designs, develops, manufactures, and commercializes injectable drug delivery systems in the United States and internationally. The company offers Unifill Syringe, a staked (fixed) retracting needle that is designed for use with liquid stable drugs; Unifill Select for use of liquid stable drug or vaccine, or a diluent to reconstitute and deliver a lyophilized drug supplied in a vial; and Unifill Assure, a finger flange and a thumb press for the intuitive self-injection of biologics. It also provides Rita disposable auto-injector that is designed to inject the prefilled dose from a single Unifill syringe; and Lisa reusable auto-injector, which automates the removal of the needle shield and enhances needle insertion and retraction, as well as EZMix dual or multi-chamber prefilled syringe for the reconstitution and delivery of injectable therapies. In addition, the company offers the Ocu-ject, a device for the delivery of microliter sized doses of drugs; and Depot-ject, a device that is designed to enable the precise placement of a drug depot into the vitreous of the eye, as well as Micro-ject, a device for optimizing the delivery of drugs with microliter doses that are unsuited to conventional device technologies. Its customers include pharmaceutical and biotechnology companies. The company is headquartered in York, Pennsylvania.

159 Employees
Last Reported Date: 09/13/13

unilife corp-cdi (UNS) Top Compensated Officers

Chairman, Chief Executive Officer, Chief Exec...
Total Annual Compensation: $420.0K
President and Chief Operating Officer
Total Annual Compensation: $330.0K
Chief Compliance Officer, Vice President, Gen...
Total Annual Compensation: $210.0K
Vice President of Corporate Quality & Regulat...
Total Annual Compensation: $203.0K
Compensation as of Fiscal Year 2012.

unilife corp-cdi (UNS) Key Developments

Unilife Corporation Announces Management Changes

Unilife Corporation has named Dennis Pyers, currently vice-president and controller, as the new interim CFO. Mr. Pyers replaces Mr. Richard Wieland who is leaving Unilife after four years as Executive vice president and CFO. Mr. Dennis P. Pyers, CPA, has served as the Chief Accounting Officer, vice president and Controller of the company since July 2010.

Unilife Corporation Announces CFO Changes

Unilife Corporation announced that Mr. Dennis Pyers, Vice-President and Controller of Unilife since 2010, has been named Interim CFO. Mr. Pyers replaces Mr. Richard Wieland who is leaving Unilife after four years as Executive Vice President and Chief Financial Officer. Mr. Dennis P. Pyers, CPA, has served as the Chief Accounting Officer, Vice President and Controller of Unilife Corporation since July 2010. Mr. Pyers spent over 25 years with KPMG, including serving as a partner from 2002 to 2009, providing a broad range of financial reporting, auditing, accounting and business advice to clients in the industrial markets and consumer products industries. He is a Certified Public Accountant licensed in Pennsylvania, Maryland and New Jersey.

Unilife Secures $60 Million Debt Financing with OrbiMed Advisors

Unilife Corporation announced that it has entered into a $60 million debt financing agreement with an affiliate of OrbiMed. $40 million was funded to Unilife at the closing of the deal. Provided the Company is in compliance with the terms of the agreement, two additional tranches of $10 million each will be provided to Unilife in December 2014 and June 2015. During the six year term of the agreement, Unilife will make interest-only payments to OrbiMed currently calculated at a rate of 10.25% per annum, with the principal to be repaid by March 12, 2020. OrbiMed will also receive a tiered royalty payment based on net sales generated by Unilife during each fiscal year of the agreement. The maximum royalty rate is 2.75% of annual net sales. The royalty rate decreases as annual net sales increases. Total royalties paid to OrbiMed under the agreement are capped as Unilife has the option to buy out the royalty payment, which is at a reduced amount at any time on or before the fourth anniversary of the agreement. No equity or warrants were or will be issued as part of this agreement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UNS:AU A$0.64 AUD 0.00

UNS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $113.16 USD +0.23
Insulet Corp $43.52 USD +0.92
Terumo Corp ¥2,113 JPY +4.00
West Pharmaceutical Services Inc $43.76 USD +0.73
Ypsomed Holding AG SFr.79.30 CHF +0.35
View Industry Companies
 

Industry Analysis

UNS

Industry Average

Valuation UNS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 258.4x
Price/Book 79.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNILIFE CORP-CDI, please visit www.unilife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.